We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

5 hedge funds and large institutions have $1.08M invested in F-star Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+5
Holders Change %
–
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PCM
Parsons Capital Management
Rhode Island
+$1.2M
2
TRCT
Tower Research Capital (TRC)
New York
+$16.9K
3
UBS Group
UBS Group
Switzerland
+$4.02K
4
Bank of America
Bank of America
North Carolina
+$2.14K
5
BIM
BlackRock Investment Management
Delaware
+$1.75K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
Parsons Capital Management
Rhode Island
$1.06M +$1.2M +27,953 New
TRCT
2
Tower Research Capital (TRC)
New York
$15K +$16.9K +396 New
UBS Group
3
UBS Group
Switzerland
$4K +$4.02K +94 New
BIM
4
BlackRock Investment Management
Delaware
$2K +$1.75K +41 New
Bank of America
5
Bank of America
North Carolina
$2K +$2.14K +50 New

FSTX Hedge Fund Activity: Q2 2016 in Review

5 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2016, worth a combined $1.08M.

Buyers outnumbered sellers: 5 funds opened new FSTX positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Parsons Capital Management, opening a new position worth an estimated $1.2M.

  • 5 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2016, up from 0 in Q1 2016.
  • Funds reported $1.08M of F-star Therapeutics, Inc. Common Stock stock for Q2 2016.
  • 5 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2016 and 0 closed out, a net change of +5 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2016 was Parsons Capital Management, an estimated $1.2M added.

Based on aggregated 13F filings for Q2 2016.